Compare RAIL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | KPTI |
|---|---|---|
| Founded | 1901 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.6M | 172.6M |
| IPO Year | 2005 | 2013 |
| Metric | RAIL | KPTI |
|---|---|---|
| Price | $13.50 | $9.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 139.4K | ★ 771.5K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $559,425,000.00 | $146,067,000.00 |
| Revenue This Year | N/A | $0.84 |
| Revenue Next Year | $18.34 | $46.25 |
| P/E Ratio | $8.65 | ★ N/A |
| Revenue Growth | ★ 56.22 | 0.57 |
| 52 Week Low | $4.31 | $3.51 |
| 52 Week High | $14.90 | $10.99 |
| Indicator | RAIL | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 57.87 |
| Support Level | $7.62 | $5.60 |
| Resistance Level | N/A | $10.99 |
| Average True Range (ATR) | 0.79 | 1.03 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 40.72 | 57.14 |
FreightCar America Inc is a manufacturer of railcars and components, serving diverse transportation needs in North America. The company designs and produces a wide range of railcar types, including box cars, hoppers, covered hoppers, gondolas, and flat cars for both intermodal and non-intermodal freight. The company has two segments: The Manufacturing segment encompasses new railcar manufacturing, used railcar sales, leasing, and rebuilds, while the Aftermarket segment includes the selling of forged, cast and fabricated railcar parts and supplies for all railcar types, and provides aftermarket services including safety training, railcar inspections, and preventative maintenance. The company's revenue is predominantly derived from its Manufacturing segment.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).